The U.S. Food and Drug Administration approved MorphoSys and Incyte’s Monjuvi (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
In a study published in Nature Medicine, scientists at Columbia University and Vanderbilt University describe how they were able to successfully restore badly damaged lungs in order to use them for lung transplants.
Menlo Park, California-based Orca Bio closed on a Series D financing worth $192 million, bringing the total raised since 2016 to $300 million.
CSL Behring, based in King of Prussia, Pennsylvania, is acquiring Vancouver, British Columbia-based Vitaeris.
Bristol-Myers and Celgene's Liso-Cel Hits Mark in Multiple Cancer StudiesAmerican Society of Hematology (ASH) Annual Meeting, B-Cell Non-Hodgkin Lymphoma, Cancer, CAR-T Therapy, Chronic Lymphocytic Leukemia (CLL), Clinical Trials, Hematopoietic Stem Cell Transplantation (HSCT), Immune Cells, R&D, Small Lymphocytic Lymphoma (SLL)
Bristol-Myers Squibb announced positive results for the CAR-T therapy lisocabtagene maraleucel (liso-cel) in three studies at the American Society of Hematology Annual Meeting.
A 17-year-old Michigan boy facing “imminent death” from vaping injuries underwent a double lung transplant, the first in a patient suffering from the effects of e-cigarettes.
The U.S. Food and Drug Administration approved Janssen’s Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant.
Akari Therapeutics Plc announced that the U.S. Food and Drug Administration granted Fast Track designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients.
Orchard Therapeutics Licenses Potentially Life-Changing MPS-I Gene Therapy ProgramADA Severe Combined Immune Deficiency (ADA-SCID), Business, Gene Therapy, Gene Transfer Technologies, Hematopoietic Stem Cell Transplantation (HSCT), Hurler syndrome (MPS I), Licensing, Neurometabolic Disorders, Stem Cell Therapy
Orchard Therapeutics secured an exclusive license for an ex vivo autologous hematopoietic stem cell gene therapy program for the treatment of MPS-I developed by SR-Tiget.
Researchers in Germany have created transparent human organs using a new technology that could pave the way to print three-dimensional body parts such as kidneys for transplants.